Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $81.42 Consensus PT from Analysts
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the ten ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price […]
More Stories
Citizens Financial Group Inc. RI Has $1.64 Million Stake in Vanguard Short-Term Corporate Bond ETF (NASDAQ:VCSH)
Citizens Financial Group Inc. RI reduced its stake in shares of Vanguard Short-Term Corporate Bond ETF (NASDAQ:VCSH – Free Report)...
FRP Holdings, Inc. (NASDAQ:FRPH) President Sells $78,750.00 in Stock
FRP Holdings, Inc. (NASDAQ:FRPH – Get Free Report) President David H. Devilliers, Jr. sold 2,500 shares of the company’s stock...
Commerce Bank Grows Holdings in Cardinal Health, Inc. (NYSE:CAH)
Commerce Bank increased its stake in Cardinal Health, Inc. (NYSE:CAH – Free Report) by 0.5% in the third quarter, Holdings...
MaxLinear, Inc. (NASDAQ:MXL) Shares Sold by Jennison Associates LLC
Jennison Associates LLC cut its position in MaxLinear, Inc. (NASDAQ:MXL – Free Report) by 2.0% in the third quarter, according...
Sezzle (NASDAQ:SEZL) Trading Up 7% Following Insider Buying Activity
Sezzle Inc. (NASDAQ:SEZL – Get Free Report) shares traded up 7% on Thursday after an insider bought additional shares in...
Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Sold by King Luther Capital Management Corp
King Luther Capital Management Corp lessened its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC – Free Report) by 27.4% during the...